Federal Policy
FDA Sends Peptide Compounding Access Policy to White House
The FDA this week submitted an "interim access policy" for peptides to the White House for regulatory review, according to a government filing. The policy would reportedly let compounding pharmacies temporarily produce and sell peptide products previously restricted by FDA rules. The filing does not specify a timeline for release or implementation. Details on scope, affected products, and effective dates remain unclear pending White House review.
Why it mattersA looser compounding policy could expand pharmacy access to peptide drugs like GLP-1 alternatives, with downstream implications for Medicaid pharmacy benefit management and utilization controls once finalized.